Related references
Note: Only part of the references are listed.Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum
Selin Oncul et al.
RNA BIOLOGY (2020)
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2019)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma
Yixin Yang et al.
CELL DEATH & DISEASE (2019)
Cancer statistics for adults aged 85 years and older, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc
Jiayin Tang et al.
NATURE COMMUNICATIONS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
LncRNA MALAT1 promotes oxidized low-density lipoprotein-induced autophagy in HUVECs by inhibiting the PI3K/AKT pathway
Shu Li et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer
Yun Wang et al.
MOLECULAR CANCER (2019)
PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis
Cristian Rodriguez-Aguayo et al.
EBIOMEDICINE (2019)
Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nuclear Long Noncoding RNAs: Key Regulators of Gene Expression
Qinyu Sun et al.
TRENDS IN GENETICS (2018)
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance
Augustin Le Naour et al.
Oncotarget (2018)
Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma
Roelants Caroline et al.
Oncotarget (2018)
Cytoplasmic functions of long noncoding RNAs
Ji Heon Noh et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2018)
The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation
Hao Wang et al.
CELL DEATH & DISEASE (2018)
Tumor evolution and chemoresistance in ovarian cancer
Soochi Kim et al.
NPJ PRECISION ONCOLOGY (2018)
Long Noncoding RNAs: At the Intersection of Cancer and Chromatin Biology
Adam M. Schmitt et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer
Cristian Rodriguez-Aguayo et al.
CELL DISCOVERY (2017)
The Dualistic Model of Ovarian Carcinogenesis Revisited, Revised, and Expanded
Robert J. Kurman et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
p110 and p110 isoforms of PI3K signaling: are they two sides of the same coin?
Paramjeet Singh et al.
FEBS LETTERS (2016)
Linking Long Noncoding RNA Localization and Function
Ling-Ling Chen
TRENDS IN BIOCHEMICAL SCIENCES (2016)
HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas
Yu Zhu et al.
ONCOTARGET (2016)
Ovarian cancer
Ursula A. Matulonis et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Seiji Mabuchi et al.
GYNECOLOGIC ONCOLOGY (2015)
The emerging role of IncRNAs in cancer
Maite Huarte
NATURE MEDICINE (2015)
Emerging Roles of Focal Adhesion Kinase in Cancer
Yu-Ling Tai et al.
BIOMED RESEARCH INTERNATIONAL (2015)
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
Bianca Cheaib et al.
CHINESE JOURNAL OF CANCER (2015)
Discovery of protein-lncRNA interactions by integrating large-scale CLIP-Seq and RNA-Seq datasets
Jun-Hao Li et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2015)
Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Christine Fritsch et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Corine M. Beaufort et al.
PLOS ONE (2014)
Transcriptional regulatory functions of nuclear long noncoding RNAs
Keith W. Vance et al.
TRENDS IN GENETICS (2014)
Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a
Er-bao Zhang et al.
ONCOTARGET (2014)
Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery
Haifa Shen et al.
CLINICAL CANCER RESEARCH (2013)
Long non-coding RNAs and human disease
Lorna W. Harries
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
Long Noncoding RNA: Its Physiological and Pathological Roles
Biao Yan et al.
DNA AND CELL BIOLOGY (2012)
The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Craig P. Carden et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Landscape of transcription in human cells
Sarah Djebali et al.
NATURE (2012)
Long non-coding RNAs and cancer: a new frontier of translational research?
R. Spizzo et al.
ONCOGENE (2012)
Frequent Genetic Abnormalities of the PI3K/AKT Pathway in Primary Ovarian Cancer Predict Patient Outcome
Jia Huang et al.
GENES CHROMOSOMES & CANCER (2011)
Non-coding RNAs as regulators of embryogenesis
Andrea Pauli et al.
NATURE REVIEWS GENETICS (2011)
The Emergence of lncRNAs in Cancer Biology
John R. Prensner et al.
CANCER DISCOVERY (2011)
Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells
Dong-Jun Peng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Subtle variations in Pten dose determine cancer susceptibility
Andrea Alimonti et al.
NATURE GENETICS (2010)
Regulation of the mammalian epigenome by long noncoding RNAs
Joanne Whitehead et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2009)
mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2009)
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
Michael A. Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis
John P. Plastaras et al.
CANCER BIOLOGY & THERAPY (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion
Sanjeev Shulkla et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery
CN Landen et al.
CANCER RESEARCH (2005)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
A du Bois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy
F Chang et al.
LEUKEMIA (2003)
Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis
A Nesterov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
